Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells

被引:32
作者
Ehinger, M
Bergh, G
Olofsson, T
Baldetorp, B
Olsson, I
Gullberg, U
机构
[1] LUND UNIV, DEPT MED, DIV HEMATOL, LUND, SWEDEN
[2] LUND UNIV, DEPT ONCOL, LUND, SWEDEN
关键词
D O I
10.1182/blood.V87.3.1064.bloodjournal8731064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leukemic U-937 cells, which lack normal p53, were stably transfected with a temperature-sensitive mutant of p53 to investigate the consequences for growth and differentiation. On induction of wild-type p53 activity at the permissive temperature, some of these cells underwent maturation as judged by the capacity for oxidative burst and the appearance of monocyte related cell surface molecules. Moreover, wild-type p53-expressing cells were more sensitive than p53-negative control cells to induction of differentiation by 1,25-dihydroxycholecalciferol; a twofold to fourfold increase of the fraction of cells showing signs of terminal maturation was observed when wild-type p53-expressing cells were incubated with 1,25-dihydroxycholecalciferol at concentrations that only slightly affected control cells. Whereas wildtype p53 activity per se induced maturation of certain cells, others underwent cell death judging from the reduced capability to exclude trypan blue and the appearance of fragmentated DNA in flow cytometric analysis. The p53-induced cell death could be inhibited by incubation with 1,25-dihydroxycholecalciferol, but not all-trans retinoic acid. Thus, 1,25-dihydroxycholecalciferol seemed to increase the survival of wild-type p53-expressing cells and to cooperate with wild-type p53 to induce differentiation. The data imply that p53-mediated maturation in U-937 cells depends on optimal regulation of signals for differentiation, survival and proliferation, and suggest a role for p53 in the differentiation induction of leukemic cells. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:1064 / 1074
页数:11
相关论文
共 58 条
[21]   USE OF ALL-TRANS RETINOIC ACID IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA [J].
HUANG, ME ;
YE, YC ;
CHEN, SR ;
CHAI, JR ;
LU, JX ;
ZHOA, L ;
GU, LJ ;
WANG, ZY .
BLOOD, 1988, 72 (02) :567-572
[22]   P53 IN HEMATOLOGIC MALIGNANCIES [J].
IMAMURA, J ;
MIYOSHI, I ;
KOEFFLER, HP .
BLOOD, 1994, 84 (08) :2412-2421
[23]  
JIANG HP, 1994, ONCOGENE, V9, P3397
[24]   GROWTH SUPPRESSION OF FRIEND VIRUS-TRANSFORMED ERYTHROLEUKEMIA-CELLS BY P53 PROTEIN IS ACCOMPANIED BY HEMOGLOBIN PRODUCTION AND IS SENSITIVE TO ERYTHROPOIETIN [J].
JOHNSON, P ;
CHUNG, S ;
BENCHIMOL, S .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (03) :1456-1463
[25]  
JOHNSON P, 1991, MOL CELL BIOL, V11, P1
[26]  
JONVEAUX P, 1991, ONCOGENE, V6, P2243
[27]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[28]  
KASTAN MB, 1991, CANCER RES, V51, P6304
[29]   WILD-TYPE P53 IS A CELL-CYCLE CHECKPOINT DETERMINANT FOLLOWING IRRADIATION [J].
KUERBITZ, SJ ;
PLUNKETT, BS ;
WALSH, WV ;
KASTAN, MB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7491-7495
[30]   P53 - ONCOGENE OR ANTI-ONCOGENE [J].
LANE, DP ;
BENCHIMOL, S .
GENES & DEVELOPMENT, 1990, 4 (01) :1-8